1 Global Recombinant Trypsin Market Insight Analysis
The global recombinant trypsin market is expected to be valued at USD 31.83 million in 2025, with a CAGR of 9.05% during 2025-2033.
Recombinant trypsin is a genetically engineered version of the enzyme trypsin, which is involved in the digestion of proteins. Recombinant trypsin is produced through recombinant DNA technology, which involves inserting the gene for trypsin into a host organism, such as bacteria or yeast, and allowing the host organism to produce the enzyme.
Figure Global Recombinant Trypsin Market Size (M USD) and CAGR (2025-2033)
2 Recombinant Trypsin Market Growth Drivers and Restraints
Downstream biopharmaceutical demand continues to grow
As a key biological reagent, recombinant trypsin is indispensable in the fields of insulin production, vaccine manufacturing and cell culture. The number of diabetes patients worldwide has increased (data from the International Diabetes Federation), driving the steady increase in demand for recombinant trypsin in insulin production. In addition, the COVID-19 epidemic has accelerated vaccine research and development and production, especially the large-scale production of inactivated vaccines and viral vector vaccines, which relies on the efficient enzymatic hydrolysis of recombinant trypsin, further driving market demand. For example, the document mentioned that the consumption of recombinant trypsin in the vaccine manufacturing field has a compound annual growth rate of 9.8% during 2018-2023, significantly higher than the industry average.
Technology substitution and safety advantages
Traditional animal-derived trypsin has the risk of viral contamination (such as bovine spongiform encephalopathy), while recombinant trypsin is produced through genetic engineering, achieving animal-free, high purity and batch-to-batch consistency, and meets the strict regulatory requirements of the Chinese Pharmacopoeia. This feature has rapidly increased its penetration in the biopharmaceutical field (such as antibodies and stem cell therapy). For example, the Chinese market has continued to expand the market share of local companies such as AsiaInfo Biopharma due to the addition of recombinant trypsin standards in the 2020 edition of the Chinese Pharmacopoeia.
The rise of emerging markets
The rapid development of the biopharmaceutical industry in the Asia-Pacific region (especially China and India) has driven the growth of demand for recombinant trypsin. As the world’s largest vaccine producer, China’s market size will reach US$333 million in 2023, with a compound growth rate of 12.79% from 2018 to 2023, far exceeding the mature markets in Europe and the United States. In addition, the localization policies of biopharmaceuticals in Southeast Asia, the Middle East and other regions (such as India’s promotion of local vaccine production) have also provided new growth points for the market.
Increased industry concentration and expansion of leading companies
The global market concentration is high, and the top three companies (Novozymes, Thermo Fisher, and AsiaInfo Biopharma) account for more than 50% of the market share. Leading companies consolidate their position through technology research and development and capacity expansion. For example, Novozymes expands application scenarios by acquiring biotechnology companies, and Thermo Fisher expands its product line through mergers and acquisitions, further promoting market growth.
Technical barriers and high R&D costs
The production of recombinant trypsin involves complex processes such as gene cloning and protein purification, which require strict control of host cell residues and endotoxin levels, and has a high technical threshold. Small and medium-sized enterprises face the problem of insufficient R&D investment, while the fermentation equipment and purification technology (such as chromatography columns and freeze-drying systems) required for large-scale production require huge investments, which limits new entrants.
Supply chain risks and dependence on raw materials
The unstable supply of upstream raw materials (such as yeast expression systems and culture medium components) may affect production. For example, as a commonly used expression host, the price fluctuations or supply disruptions of Pichia pastoris will directly affect costs. In addition, global logistics bottlenecks (such as cross-border transportation restrictions during COVID-19) have caused supply chain disruptions in some regions, exposing the vulnerability of the supply chain.
Price competition and cost pressure
Solid dosage recombinant trypsin occupies a dominant market (76% revenue share), but price competition is fierce. Chinese companies have seized the market with cost advantages (such as AsiaInfo Bio’s prices are 30-50% lower than those of international giants), resulting in international manufacturers facing price reduction pressure. At the same time, labor costs (such as labor costs in the European and American manufacturing industries account for more than 15%) and energy consumption (freeze-drying processes consume a lot of energy) continue to rise, compressing corporate profit margins.
Strict regulatory supervision and market access
Regulations in different regions vary significantly (such as FDA’s cGMP requirements for biological products and EMA’s EDQM certification). Companies need to invest a lot of resources to meet compliance, which slows down the launch of new products. For example, due to strict biosafety reviews in the Japanese market, the import process of recombinant trypsin is complicated, resulting in limited market share for local companies.
Potential threats from alternative technologies
Although recombinant trypsin has replaced most animal-derived products, it still faces competition from other proteases (such as pepsin and pronase) in some special scenarios (such as enzymatic reactions under extreme pH environments). In addition, advances in serum-free culture medium technology may reduce dependence on trypsin, which may have a long-term impact on the market.
3 Technological Innovations in the Recombinant Trypsin Market
Production process optimization and efficiency improvement
Host system innovation: Enterprises gradually shift from Escherichia coli to yeast (such as Pichia pastoris) and insect cell expression systems to improve the folding efficiency and post-translational modification level of recombinant proteins. For example, Roche uses the Pichia pastoris expression system to achieve high activity (≥180 U/mg) and low endotoxin (≤100 CFU/mL) of recombinant trypsin.
Purification technology upgrade: The application of chromatography technology (such as affinity chromatography, ion exchange chromatography) and membrane separation technology has significantly improved product purity (≥95%) and shortened the production cycle. Novozymes has increased the purification yield from 70% to 85% by optimizing the chromatography process.
Product dosage form innovation and application expansion
Popularization of liquid dosage forms: Liquid dosage forms have a significant increase in demand in the field of cell therapy and rapid testing due to their convenience (no need to dissolve) and improved stability (such as Sartorius’s Accutase® solution can be stored at room temperature for 24 months). In 2023, liquid dosage form revenue accounted for 23.9%, with an annual growth rate of more than 10%.
Development of special functional products: In response to the needs of stem cell culture and gene therapy, the company has developed animal-free (ADCF) and phenol red-free special trypsin, such as BasalMedia’s Trpzyme® solution, to meet the requirements of high-sensitivity experiments.
Sustainable production and green technology
Leading companies promote low-carbon production. For example, Merck reduces energy consumption by 30% by optimizing fermentation processes, and Novozymes uses renewable energy to drive production facilities to respond to the EU Green New Deal and China’s “dual carbon” goals and enhance corporate ESG competitiveness.
Corporate mergers and acquisitions and restructuring trends
Horizontal mergers and acquisitions expand market share
Novozymes: Acquired agricultural technology company Biotalys in 2022 to expand enzyme applications in the field of biocontrol and indirectly enhance its layout in the upstream raw material market of biopharmaceuticals.
Thermo Fisher: Completed the acquisition of The Binding Site Group (worth $2.8 billion) in 2023, integrating its diagnostic business while acquiring recombinant protein production technology to strengthen its leadership in the field of life science tools.
Vertical integration optimizes the supply chain
Yaxin Bio: By participating in upstream culture medium suppliers, it ensures a stable supply of key raw materials (such as yeast extract) and reduces external dependence. At the same time, it establishes its own purification equipment production line to reduce production costs by about 20%.
Merck: Acquired Imago BioSciences (US$1.35 billion) to expand the application of enzymes in the field of hematology and form an integrated chain of “R&D-production-application”.
Regional market expansion and localized cooperation
Sartorius: In 2019, it acquired a majority stake in Israel’s Biological Industries, strengthened its layout in the Middle East and Asia-Pacific in the cell culture medium and trypsin markets, and used its local production capacity to radiate emerging markets.
Novozymes cooperates with Chinese companies: Establishing a production base in China through a joint venture model, launching low-cost solid dosage forms for the Chinese market, responding to competition from local companies while reducing the impact of tariffs.
4 Global Recombinant Trypsin Market Size by Type
The solution type of Recombinant Trypsin is expected to generate a revenue of $7.73 million USD in 2025, accounting for 24.28% of the total market revenue. This type is particularly favored for its ease of use and suitability for a wide range of biotechnological processes, including cell culture and vaccine production. The solution form is often preferred in applications where gentle handling of cells is required, such as in the detachment of cells for analysis or in the production of therapeutic cells. Its market share is anticipated to grow steadily due to its versatility and the increasing demand for non-animal-derived alternatives in biopharmaceutical processes.
The solid type of Recombinant Trypsin is projected to have a significantly larger market revenue of $24.11 million USD in 2025, representing 75.72% of the total market revenue. Solid Recombinant Trypsin is typically provided as a lyophilized powder, which offers advantages such as long-term stability and ease of storage and transportation. This form is widely used in applications requiring high enzyme activity and purity, such as insulin manufacturing and vaccine production. The solid type is particularly preferred in industrial-scale processes due to its stability and consistency, which are critical for large-scale biopharmaceutical production.
Table Global Recombinant Trypsin Market Size and Share by Type in 2025
Type | Market Size (M USD) 2025 | Market Share 2025 |
|---|---|---|
Solution | 7.73 | 24.28% |
Solid | 24.11 | 75.72% |
5 Global Recombinant Trypsin Market Size by Application
Insulin manufacturing is one of the significant applications of recombinant trypsin. In 2025, the market revenue for recombinant trypsin in insulin manufacturing is projected to be 12.65 million USD. This accounts for 39.73% of the total market share. The demand for insulin has been on the rise globally due to the increasing prevalence of diabetes. Recombinant trypsin plays a vital role in the production process of insulin, ensuring the proper enzymatic reactions that are essential for the synthesis of this life – saving hormone. As the number of diabetes patients continues to grow, the need for insulin production is expected to remain stable, thereby sustaining the demand for recombinant trypsin in this application.
Vaccines manufacturing is another major area where recombinant trypsin is extensively used. In 2025, the market revenue for this application is forecasted to be 15.09 million USD, which takes up 47.39% of the total market share. The COVID – 19 pandemic has highlighted the importance of vaccines, and the global push for vaccine development and production has significantly increased the demand for recombinant trypsin. In vaccine manufacturing, recombinant trypsin is used in processes such as cell culture and antigen production.
It helps in the growth and maintenance of cells that are used to produce vaccines, ensuring the quality and effectiveness of the final product. With the continuous efforts in vaccine research and development for various diseases, the market for recombinant trypsin in vaccines manufacturing is likely to experience further growth in the coming years.
Cell culture is also an important application field for recombinant trypsin. In 2025, the market revenue for recombinant trypsin in cell culture is expected to be 4.10 million USD, accounting for 12.88% of the total market share. Cell culture is a fundamental technique in biological research and biopharmaceutical production. Recombinant trypsin is used to dissociate cells from the culture surface or to break down cell aggregates, enabling researchers to study cells in a controlled environment. As the fields of regenerative medicine, drug discovery, and personalized medicine continue to advance, the demand for cell culture – based research and production will increase, which in turn will drive the demand for recombinant trypsin in this application.
Table Global Recombinant Trypsin Market Size and Share by Application in 2025
Application | Market Size (M USD) 2025 | Market Share 2025 |
|---|---|---|
Insulin Manufacturing | 12.65 | 39.73% |
Vaccines Manufacturing | 15.09 | 47.39% |
Cell Culture | 4.10 | 12.88% |
6 Global Recombinant Trypsin Market Size by Region
In 2025, the United States is projected to lead the global Recombinant Trypsin market with a revenue of $9.54 million USD. This represents a significant growth from the previous years, reflecting the region’s robust biopharmaceutical industry and the high demand for advanced biotechnological products. The United States has a well-established infrastructure for research and development, coupled with strong regulatory support, which fosters innovation in the biopharmaceutical sector. The growth in this region is also attributed to the increasing prevalence of chronic diseases like diabetes, which drives the demand for insulin and other biopharmaceuticals that utilize Recombinant Trypsin in their production processes.
Europe is expected to follow closely with a market revenue of $9.07 million USD in 2025. The European market is characterized by a strong emphasis on quality and safety standards, which drives the demand for Recombinant Trypsin. The region’s biopharmaceutical industry is highly regulated, ensuring that products meet the highest standards of efficacy and safety. This focus on quality has made European products highly sought after globally. Additionally, the presence of numerous biopharmaceutical companies and research institutions in Europe contributes to the region’s significant share of the global market. The growth in this region is also supported by increasing investments in healthcare and biopharmaceutical research.
China is anticipated to be a significant contributor to the global market, with a projected revenue of $4.07 million USD in 2025. The Chinese market is rapidly growing due to factors such as increasing healthcare expenditure, a growing middle class with higher healthcare needs, and significant government investments in the biopharmaceutical sector. China’s biopharmaceutical industry is expanding rapidly, with a focus on both domestic consumption and export. The country’s strategic initiatives to boost domestic production capabilities and reduce reliance on imports are expected to drive the demand for Recombinant Trypsin. Moreover, China’s large patient population base and the increasing incidence of diseases that require biopharmaceutical treatments further fuel the market’s growth.
Figure Global Recombinant Trypsin Market Size (M USD) by Region in 2025
7 Global Recombinant Trypsin Market Analysis by Major Players
Novozymes
Company Profile: Novozymes, established in the year 2000 and headquartered in Denmark, has emerged as a leading player in the biopharmaceutical industry. The company operates worldwide, providing a broad range of enzymes and microorganisms that are crucial for various industrial processes.
Business Overview: Novozymes specializes in the production of industrial enzymes and microorganisms used in biopharmaceutical manufacturing, food, agriculture, and other industrial applications. The company’s commitment to innovation and sustainability has helped it maintain a strong presence in the global market. Novozymes invests heavily in research and development to ensure that its products meet the highest standards of quality and efficiency.
Product Offered: Novozymes offers rTrypsin® Granulate, a recombinant product manufactured by microbial fermentation. This product is a serine protease with a unit activity of 800 USP/m and is suitable for a range of biotechnological processes. Unlike native trypsin, rTrypsin® Granulate is animal component-free, meeting stringent safety regulations for biologicals and biopharmaceuticals. It is used for cell dissociation, vaccine production, and cleavage of proinsulin to yield intact insulin.
Thermo Fisher Scientific
Company Profile: Thermo Fisher Scientific, founded in 1956 and headquartered in the USA, is a global leader in serving science. The company provides advanced products and services for life sciences research, healthcare, and applied markets.
Business Overview: Thermo Fisher Scientific operates globally, offering a wide array of products including laboratory equipment, consumables, software, and services. The company is known for its innovative solutions that support scientific discovery, enhance healthcare diagnostics, and improve patient care. Thermo Fisher’s strong R&D capabilities and strategic acquisitions have helped it expand its product portfolio and market reach.
Product Offered: Thermo Fisher offers TrypLE™ Select CTS™, a recombinant enzyme obtained by microbial fermentation. This product serves as a non-animal source alternative to porcine trypsin. It is used for dissociating attachment-dependent cell lines from plasticware and is suitable for both serum-free and serum-supplemented culture systems. TrypLE™ Select CTS™ is stable at room temperature and is produced using dedicated autoclavable or disposable equipment, ensuring high safety standards.
Yaxin Bio
Company Profile: Yaxin Bio, established in 2008 and headquartered in China, is a global provider of biological products. The company has a strong presence in the market, offering a wide range of products for research and industrial applications.
Business Overview: Yaxin Bio focuses on the development and production of high-quality biological products, including enzymes, antibodies, and cell culture media. The company’s commitment to quality and innovation has made it a preferred supplier for many research institutions and pharmaceutical companies worldwide. Yaxin Bio continuously invests in expanding its product range and improving its production capabilities to meet the growing demand for biological products.
Product Offered: Yaxin Bio provides Recombinant Trypsin freeze-dried powder, which is expressed and produced by recombinant Escherichia coli. This product is used for cell digestion processes in various fields, including vaccines, stem cells, immune cell therapy, drug screening, and antibodies. It complies with Pharmacopoeia standards, is free from animal-derived components, and offers stable quality with high purity. The product is easy to store and transport, making it a convenient choice for various applications.